Jump to content
Main menu
Main menu
move to sidebar
hide
Navigation
Main Page
My Profile
My Assessments
My Life Story
Med Classes
Problems
Recent changes
Pharmacopedia
Search
Search
Appearance
Create account
Log in
Personal tools
Create account
Log in
Drilldown: Medicines
English
Tools
Tools
move to sidebar
hide
Actions
General
Printable version
Appearance
move to sidebar
hide
Choose a table:
Medicines (732)
Medicines
> duration:
4-6 hours
&
bioavailability:
Tramadol ~75% (oral); acetaminophen 85-98%'"`UNIQ--ref-00001531-QINU`"'
Use the filters below to narrow your results.
generic:
Tramadol / Acetaminophen (1)
brand:
Ultracet, Tramacet (1)
classes:
None
(1)
mechanism:
None
(1)
uses:
'"`UNIQ--vote-0000152F-QINU`"' (1)
starting dose:
2 tablets (75 mg tramadol / 650 mg acetaminophen) PO every 4-6 hours as needed; maximum 8 tablets/day for ≤5 days (1)
preparations:
Tramadol/acetaminophen 37.5/325 mg tablets (1)
fda max:
8 tablets/d (300 mg tramadol / 2600 mg acetaminophen); 5-day duration limit per label (1)
routes:
Oral (1)
onset:
30-60 minutes (1)
duration:
(Click arrow to add another value)
None
·
24 hours
· 4-6 hours ·
12 hours
·
6-8 hours
·
Daily dosing
·
8-12 hours
·
12-24 hours
·
Hours
·
Hours per application
·
24 hours (HS dosing)
·
24 hours (once-daily dosing)
·
24 h
·
N/A
·
N/A (replacement)
·
Variable
·
~7-8 hours
·
3-5 hours
·
4-6 hours (IR); 24 hours (ER)
·
6-12 hours
Other values:
'''Antiplatelet effect lasts the platelet's lifetime (~7-10 days)''' due to irreversible COX-1 acetylation; analgesic 4-6 hours
10-12 hours (smoother profile than immediate-release amphetamine salts)
12 hours (BID dosing required)
12 hours (IR); 24 hours (ER)
12 hours (Macrobid)
12 hours (oral BID); 24 hours (Timoptic-XE)
12-24 hours (IR BID); 24 hours (ER once-daily)
12-24 hours (IR); 24 hours (Amrix ER)
12-24 hours (long for an antihistamine)
12-24 hours per dose
12–24 h (oral); decanoate IM 3–4 weeks
12–24 h or longer
14-day course; effect persists after discontinuation in trials
2 weeks per dose
2-4 hours; headache recurrence rate ~20-30% within 24 hours
2-4 weeks per dose
2-5 days after stopping (factor II resynthesis-limited)
24 hours (0.7% formulation); 8-12 hours (lower-strength)
24 hours (XR); 12 hours (IR)
24 hours (evening dosing aligns with overnight HMG-CoA reductase peak)
24 hours (long receptor dissociation half-life from M3)
24 hours (most ER formulations)
24 hours (often divided BID at higher doses)
24 hours (once-daily dosing supported by long elimination)
24 hours (once-daily dosing supported by long half-life)
24 hours (once-daily or split BID dosing)
24 hours (oral); 2-4 weeks (LAI formulations)
24 hours (oral); 2-4 weeks (LAI)
24 hours (oral); 4-8 weeks (LAI)
24 hours; tissue effects persist weeks
24+ hours (irreversible enzyme binding)
24-48 hours per dose
24-72 hours
24-72 hours per dose (irreversible enzyme binding)
24-72 hours per dose (irreversible enzyme binding; effect outlasts plasma exposure)
24–36 h (driven by buprenorphine)
2–4 h
3-4 hours
3-5 hours (IR); 8-24 hours (ER); 12-24 hours (epidural / intrathecal)
3-6 hours per dose
3-8 hours
3-month dosing interval
30-90 minutes (infiltration without epinephrine); 90-200 minutes (with epinephrine); 12 hours (patch)
3–4 h
3–5 h (subjective)
4 hours
4 hours (IR); 12 hours (ER)
4-12 hours
4-6 hours (IR); 12 hours (ER)
4-6 hours (IR); 12-24 hours (ER)
4-6 hours (oral, TID-QID dosing)
4-6 hours; headache recurrence is common
4-8 h
4-8 hours
4-8 hours typical; longer at high doses; residual cognitive and perceptual effects up to 48 hours
48-72 hours per dose (much longer than hydrochlorothiazide)
4–5 h
4–6 h
4–6 hours
5-15 minutes
5-7 days (platelet lifespan; irreversible receptor binding)
6 h (immediate-release); ~11 h (extended-release)
6 hours per dose
6-12 hours (long-acting among benzodiazepines)
6-12 hours systemic
6-24 hours (parent); much longer when accounting for the long-lived active metabolites
6-8 h (immediate-release); 24 h (extended-release)
6-8 hours (IR oral); 12-24 hours (ER)
6-8 hours (IR); 24 hours (ER)
6-8 hours (IR); 8 hours (CR via biphasic release)
6–10 h subjective; full pharmacologic effect considerably longer.
6–12 h (IR); 24 h (ER)
6–12 h (tartrate); 24 h (succinate)
6–8 h
8 hours per dose
8 hours per oral dose
8-12 hours (IR); ~7 days (transdermal patch)
8-12 hours (TID dosing needed)
8-12 hours (oral); 4-6 hours (IV)
8-12 hours (the long-duration feature relative to ibuprofen)
8–12 hours
>42 hours per dose (effectively flat once at steady state)
About 20 minutes
Acute effect ~24 hours; cumulative effect builds with repeated dosing
BID at higher doses (IR); once-daily (CR)
BID dosing (IR); once-daily (XR)
BID dosing for IR; once-daily for XR
BID-QID dosing (IR); BID for ER formulations
BID-TID dosing
BID-TID dosing for IR; once-daily for CR
Biologic 12-36 hours (intermediate-acting)
Biologic 12-36 hours (intermediate-acting); Depo-Medrol depot weeks
Biologic 36-54 hours (long-acting)
Biologic 36-72 hours (long-acting)
Biologic half-life ~12-36 hours (intermediate-acting); plasma half-life shorter
Biologic ~8-12 hours (short-acting)
Chronic daily dosing
Continuous daily dosing
Daily dosing; active metabolites with very long half-lives (up to 1-3 weeks)
Daily morning dosing
Depot IM 13 weeks (designed); often persists longer
Dosing-frequency dependent
Hours (nasal); ~24 h (gel/patch); 1–2 weeks (cypionate/enanthate IM); ~10 weeks (undecanoate IM)
Hours per application (topical); 24 hours (oral)
Hours per dose
Hours per dose (much shorter biologic effect than ergocalciferol/cholecalciferol because it is the already-active form, not the storage form)
Hours per topical application
Hours to days per application
IM benzathine: 3-4 weeks of detectable levels
IR 3–5 h; LA/SR 6–8 h; Concerta 10–12 h; Daytrana ~9 h wear time
IR 4-8 hours; ER 24 hours
IR 4–6 h; XR 10–12 h; Mydayis 14–16 h
IR 4–6 h; XR 8–12 h
IR: 4-8 hours; ER: 24 hours
IR: 6-10 hours; ER: 24 hours
IR: 6-8 hours; ER: 24 hours
IV: 1-4 hours; PO: 3-8 hours
IV: hours, dependent on ongoing acid load; oral antacid: ~30 minutes
IV: ~2 hours; PO: 6-8 hours
Intra-articular 3-6 months (depot effect of acetonide microcrystals)
Long
Long; fat-soluble storage in adipose
Long; fat-soluble, stored in adipose
Mononitrate ER: 12-24 hours; dinitrate IR: 4-6 hours
Monthly dosing
Monthly or quarterly dosing
Once-weekly dosing in rheumatology
Ongoing dosing
Oral: 8-12 hours; vaginal: 24+ hours; IM: days
Persistent activity 6+ hours (residual binding to skin and oral surfaces)
Roughly 20-25% of an IV bolus remains intravascular at 1 hour
Roughly 20-30% remains intravascular at 1 hour
Route- and formulation-dependent
SL: 30 minutes; patch: 12-14 hours; IV continuous
SR ~12 hours; XL 24 hours
Single infusion course
Steady-state at 4-6 weeks
Sustained with twice-daily dosing
TID dosing (IR); once-daily (ER)
TID dosing (IR); once-daily (XL)
TID dosing for IR; once-daily for ER formulations
Tissue half-life supports once-daily and post-treatment effect
Treatment can be discontinued upon achieving amyloid clearance
Up to 36 h ("the weekend pill")
Variable; biologically active metabolite carries effect beyond plasma half-life
Variable; depends on ongoing losses
Very long
Weeks (fat-soluble)
Weeks (long half-life)
Weeks after discontinuation (extremely long half-life)
Weeks; bone retention years
Withdrawn
~10 hours (Byetta)'"`UNIQ--ref-000000EB-QINU`"' · ~7 days steady-state (Bydureon, after ~6–7 weeks of weekly dosing to reach steady state)'"`UNIQ--ref-000000EC-QINU`"'
~12 hours (IR); 24 hours (CR)
~12 hours (IR); 24 hours (ER)
~12 weeks
~12-14 hours
~12-24 hours
~12-24 hours (dose-dependent; BID dosing often needed at higher doses)
~15 min
~24 h (daily dosing)'"`UNIQ--ref-00000189-QINU`"'
~24 hours (ER formulation supports once-daily dosing)
~24 hours per dose (peakless profile by design)
~24 hours per dose (strict timing required for POP — within 3-hour window each day)
~3 h per dose (twice-nightly schedule required)
~4 h
~48 h sustained pain freedom in responders
~48 hours of headache freedom
~6-8 hours (IR); 24 hours (Oleptro ER)
~7 days (weekly SC dosing)'"`UNIQ--ref-00000251-QINU`"' · ~24 h (oral)'"`UNIQ--ref-00000252-QINU`"'
~7 days (weekly dosing)'"`UNIQ--ref-00000058-QINU`"'
~7 days (weekly dosing)'"`UNIQ--ref-00000302-QINU`"'
~8 hours (TID dosing)
~8 hours per dose
~9 hours
Search
halflife:
Tramadol ~5-7 hours (M1 metabolite ~9 hours); acetaminophen 1-3 hours'"`UNIQ--ref-00001530-QINU`"' (1)
bioavailability:
(Click arrow to add another value)
None
·
100% (IV)
·
~100% from subcutaneous depot
·
~80% (oral)'"`UNIQ--ref-00000027-QINU`"'
·
70–90% (oral)
·
~100% (oral)'"`UNIQ--ref-0000001C-QINU`"'
·
~50% (oral)'"`UNIQ--ref-00000021-QINU`"'
·
~95%
·
'''Saturable''' via the LAT-1 amino-acid transporter, producing nonlinear pharmacokinetics: ~60% at 300 mg single dose, falling to ~35% at 1200 mg single dose'"`UNIQ--ref-0000002A-QINU`"'
·
10-20% (oral; reduced by food, calcium, antacids, PPIs, tea/coffee; enhanced by ascorbate)
·
100% (IV); essentially complete (oral)
·
100% (IV); rapidly neutralized by gastric acid (oral)
·
16-21% capsule, 25% suspension (oral; iron and antacids reduce absorption substantially)'"`UNIQ--ref-000009E5-QINU`"'
·
25 mg: ~29%; 50 mg: ~35%; food reduces absorption'"`UNIQ--ref-00000C4F-QINU`"'
·
30-40% (oral; increases with repeated dosing as gastric pH rises)'"`UNIQ--ref-000000DF-QINU`"'
·
40-45% (oral; not significantly affected by food)'"`UNIQ--ref-0000025C-QINU`"'
·
40-80% (oral); reduced by food, calcium, iron, PPIs, fiber; take fasting with water'"`UNIQ--ref-00000037-QINU`"'
·
42-58% (oral; dose-dependent)'"`UNIQ--ref-00000AEF-QINU`"'
·
50-60% (oral; decreased with food, but food given anyway for GI tolerance)'"`UNIQ--ref-00000019-QINU`"'
·
60-70% PO at low doses; saturable at high doses (parenteral routes preferred above 15-25 mg/week)'"`UNIQ--ref-000007C9-QINU`"'
Other values:
60-80% (oral)
60-80% (oral; not significantly affected by food)'"`UNIQ--ref-00000843-QINU`"'
64-90% (oral; not affected by food)'"`UNIQ--ref-00000079-QINU`"'
65-75% (oral)'"`UNIQ--ref-0000013F-QINU`"'
70-75% (oral)'"`UNIQ--ref-000007ED-QINU`"'
70-80% (oral)'"`UNIQ--ref-000002A4-QINU`"'
75-90% (oral; minimally affected by food)'"`UNIQ--ref-000001A2-QINU`"'
80-90% oral
90% (oral; food delays but does not reduce absorption)'"`UNIQ--ref-000004F3-QINU`"'
<0.1% systemic absorption (PEG 3350 is too large to absorb intact)
<1% (oral; further reduced by food, calcium, iron, antacids; hence the strict fasting/upright dosing rules)'"`UNIQ--ref-000006C4-QINU`"'
<1% oral (extensive first-pass via CYP3A4); ~30% inhaled lung deposition'"`UNIQ--ref-000001DE-QINU`"'
<3% systemic absorption (the basis of the safety and mechanism)'"`UNIQ--ref-00000F5E-QINU`"'
<5% (extensive hepatic first-pass; food enhances absorption of IR, hence the evening-meal dosing)'"`UNIQ--ref-00000808-QINU`"'
<5% (extensive hepatic first-pass; statin pharmacology is hepatocellular, not systemic)'"`UNIQ--ref-0000017B-QINU`"'
<5% systemic absorption (this is the safety basis)'"`UNIQ--ref-00000DC3-QINU`"'
>90% (oral)'"`UNIQ--ref-0000001C-QINU`"'
>90% (oral; food slows absorption and reduces peaks, hence the post-meal dosing rule)'"`UNIQ--ref-000001BD-QINU`"'
>90% (oral; not affected by food or gastric pH — a major practical advantage over itraconazole)'"`UNIQ--ref-00000A48-QINU`"'
>90% (oral; not significantly affected by food)'"`UNIQ--ref-00001120-QINU`"'
Absolute bioavailability not precisely characterized; food modestly increases exposure
Acid-labile; not effective orally (oral form available outside US as penicillin G salts but penicillin V is preferred for oral use)'"`UNIQ--ref-0000141A-QINU`"'
Adequate (food-dependent, must take with fatty meal)
Adequate oral bioavailability
Adequate oral bioavailability with extended-release formulation
Buprenorphine ~30% SL; naloxone <10% SL (intentional, inactive sublingually, matters only if injected)
Butalbital well-absorbed; aspirin 50-75%; caffeine ~100%'"`UNIQ--ref-000015B8-QINU`"'
Butalbital well-absorbed; caffeine ~100%; acetaminophen 85-98%'"`UNIQ--ref-000015A0-QINU`"'
Carbonate ~30-40% (best with food and acid); citrate ~24% (absorbable without acid; preferred in achlorhydria, PPI use, post-bariatric)
Codeine ~60% (oral); acetaminophen 85-98%'"`UNIQ--ref-00001518-QINU`"'
Essentially zero systemic absorption from oral or topical routes — the topical-action-only profile is the basis of its safety'"`UNIQ--ref-00000D18-QINU`"'
High (oral)
High (oral); not significantly affected by food'"`UNIQ--ref-00000397-QINU`"'
High (oral)'"`UNIQ--ref-00000FB5-QINU`"'
High (oral)'"`UNIQ--ref-00001051-QINU`"'
High (oral)'"`UNIQ--ref-00001165-QINU`"'
High (oral)'"`UNIQ--ref-000012A0-QINU`"'
High (oral; absorption not affected by food)'"`UNIQ--ref-00000825-QINU`"'
High (oral; food enhances)'"`UNIQ--ref-00001039-QINU`"'
High (oral; food prolongs absorption modestly)'"`UNIQ--ref-00000622-QINU`"'
High (oral; not affected by food, but typically given with the morning meal)'"`UNIQ--ref-0000027D-QINU`"'
High (oral; not significantly affected by food)'"`UNIQ--ref-00000B65-QINU`"'
High with fat-containing meal; reduced in malabsorption
Highly formulation-dependent; the goal is colonic delivery with minimal systemic exposure'"`UNIQ--ref-00000BBF-QINU`"'
Highly route-dependent: SL bypasses first-pass; oral has extensive first-pass (used only for chronic ER preparations); transdermal predictable'"`UNIQ--ref-00000C10-QINU`"'
Highly salt-dependent: citrate ~25-30%; oxide ~4% (limited and causes osmotic diarrhea); chloride ~12%
Highly variable due to saturable first-pass metabolism'"`UNIQ--ref-0000002C-QINU`"'
IM/SC ~100%; oral negligible (extensive first-pass and gut metabolism — hence the no-oral route)'"`UNIQ--ref-00000E53-QINU`"'
IV/IM ~100%; inhaled: minimal systemic; oral: negligible (not used orally for systemic infection)'"`UNIQ--ref-000010B4-QINU`"'
Improved with food'"`UNIQ--ref-00000052-QINU`"'
Increased substantially via CYP2D6 inhibition'"`UNIQ--ref-00001584-QINU`"'
Increased with food (varies by formulation; the micronized and nanocrystal forms are less food-dependent)'"`UNIQ--ref-000004AE-QINU`"'
Inhaled lung deposition with minimal systemic absorption (the basis of the favorable safety profile vs systemic antimuscarinics)'"`UNIQ--ref-00000F7C-QINU`"'
Inhaled lung deposition ~20%; systemic absorption from lung ~33%; oral component negligible'"`UNIQ--ref-000009C1-QINU`"'
Intranasal ~40% systemic; ophthalmic minimal'"`UNIQ--ref-000013B7-QINU`"'
Intranasal: <1% systemic; inhaled lung deposition with extensive first-pass clearance'"`UNIQ--ref-00000F9D-QINU`"'
Limited but adequate; take with food
Local (intramuscular)
Local action; minimal systemic effect
Low systemic absorption (enteric coating delivers drug to colon)'"`UNIQ--ref-0000106C-QINU`"'
Mononitrate ~100% (no first-pass; the principal advantage over dinitrate); dinitrate ~20%'"`UNIQ--ref-00001462-QINU`"'
Naltrexone ~5% (oral, extensive first-pass to 6β-naltrexol); bupropion ER ~87%'"`UNIQ--ref-00001569-QINU`"'
Negligible (not absorbed)'"`UNIQ--ref-00000058-QINU`"'
Negligible systemic absorption'"`UNIQ--ref-0000119D-QINU`"'
Not characterized; oral dosing once daily
Not formally characterized for the combination
Not formally characterized in humans.
Not formally established
Not formally established (high SC)
Not formally established; oral once-daily adequate
Not well characterized
Not well characterized'"`UNIQ--ref-00000019-QINU`"'
Olanzapine 60% (oral); fluoxetine high (oral)'"`UNIQ--ref-0000154E-QINU`"'
Oral bioavailability of psilocin from administered psilocybin approximately 50%
Oral bioavailability suitable for daily dosing
Oral non-undecanoate has essentially zero bioavailability (hepatic first-pass)
Oral ~1-3% via passive diffusion at high doses (independent of intrinsic factor); IM/SC ~100%
Oral ~5% (extensive first-pass to estrone and conjugates); transdermal bypasses first-pass, giving more physiologic estradiol:estrone ratio'"`UNIQ--ref-000003BB-QINU`"'
Oral ~70%; depot IM provides sustained release over weeks'"`UNIQ--ref-0000101B-QINU`"'
Oral ~90%; depot IM essentially 100% over the dosing interval'"`UNIQ--ref-00000F21-QINU`"'
Oral: very low (extensive first-pass); micronization improves uptake somewhat. Vaginal: high local effect with lower systemic levels (first-uterine-pass concentration)'"`UNIQ--ref-00000727-QINU`"'
Oxycodone 60-87%; aspirin 50-75%'"`UNIQ--ref-000014FB-QINU`"'
Rapid absorption; absolute bioavailability not formally established
Reasonable (not formally established as a percentage)
SC ~47%–65%'"`UNIQ--ref-0000005A-QINU`"'
SC ~55%'"`UNIQ--ref-0000018B-QINU`"'
SC ~65%–75%<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup>
SC ~80%<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup>
SC ~89%<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> · Oral ~0.4–1% (SNAC-enhanced)'"`UNIQ--ref-00000254-QINU`"'
Sandimmune: highly variable (~30%); Neoral microemulsion: ~50%, less variable; '''Sandimmune and Neoral are NOT bioequivalent and not interchangeable''''"`UNIQ--ref-00000A92-QINU`"'
Substantially improved with high-fat meal; take with food'"`UNIQ--ref-000013D2-QINU`"'
Sumatriptan ~15% (oral; substantial first-pass); naproxen ~95%'"`UNIQ--ref-000015D2-QINU`"'
Tablet ~100% relative to oral solution; extensive first-pass metabolism
Topical with limited but measurable systemic absorption'"`UNIQ--ref-00001219-QINU`"'
Topical with measurable systemic absorption (small CA inhibition observed clinically with chronic use)'"`UNIQ--ref-00000B0B-QINU`"'
Topical with minimal systemic absorption'"`UNIQ--ref-000011DA-QINU`"'
Topical with minimal systemic absorption'"`UNIQ--ref-0000123A-QINU`"'
Topical with minimal systemic absorption'"`UNIQ--ref-00001288-QINU`"'
Topical with variable systemic absorption depending on body site, occlusion, and skin integrity; HPA-axis suppression is documented even with brief courses to large areas'"`UNIQ--ref-0000079F-QINU`"'
Topical/intranasal: high local, low systemic; intra-articular: local depot then systemic absorption'"`UNIQ--ref-00000667-QINU`"'
Topical/oral local action with minimal systemic absorption'"`UNIQ--ref-00001399-QINU`"'
Topical: local effect on enamel; systemic supplementation has high oral bioavailability with skeletal accumulation
Topical: minimal systemic absorption (oral systemic 5-FU not used due to poor and variable absorption)'"`UNIQ--ref-000011BF-QINU`"'
Topical: minimal systemic absorption with normal skin; oral: variable, induced metabolism with repeated dosing'"`UNIQ--ref-00000BA4-QINU`"'
Topical: minimal systemic; oral: pH-dependent, requires gastric acid'"`UNIQ--ref-00000889-QINU`"'
Topical: minimal systemic; troche: ~3% systemic'"`UNIQ--ref-00000F46-QINU`"'
Topical; clinically meaningful systemic absorption can produce systemic α2 effects (somnolence, hypotension), especially in children'"`UNIQ--ref-000010D2-QINU`"'
Topical; minimal systemic absorption'"`UNIQ--ref-00000418-QINU`"'
Topical; minimal systemic absorption'"`UNIQ--ref-00000A03-QINU`"'
Topical; minimal systemic absorption'"`UNIQ--ref-00000DA2-QINU`"'
Tramadol ~75% (oral); acetaminophen 85-98%'"`UNIQ--ref-00001531-QINU`"'
Variable (oral; rapidly conjugated to active glucuronide; food does not affect)'"`UNIQ--ref-00000451-QINU`"'
Variable; reduced by food, calcium, iron, PPIs'"`UNIQ--ref-00000037-QINU`"'
~0.3% (oral; extensive first-pass via CYP3A4 and P-glycoprotein-mediated efflux at the intestinal and blood-brain barriers limit systemic and CNS exposure at therapeutic doses)'"`UNIQ--ref-00000FD3-QINU`"'
~10% inhaled reaches systemic circulation; ~50% PO'"`UNIQ--ref-0000009A-QINU`"'
~100% (oral); highly (~90%) protein-bound, with non-linear binding above therapeutic levels (free fraction matters clinically in hypoalbuminemia)'"`UNIQ--ref-0000097D-QINU`"'
~100% (oral)'"`UNIQ--ref-0000001B-QINU`"'
~100% (oral)'"`UNIQ--ref-00000020-QINU`"'
~100% (oral)'"`UNIQ--ref-00000027-QINU`"'
~100% (oral)'"`UNIQ--ref-00000706-QINU`"'
~100% (oral, but oral use is limited to continuation from parenteral)'"`UNIQ--ref-00000021-QINU`"'
~100% (oral; absorption complete)'"`UNIQ--ref-0000126F-QINU`"'
~100% (oral; food delays absorption, hence pre-meal dosing for IR)'"`UNIQ--ref-000002DA-QINU`"'
~100% (oral; near-complete absorption)'"`UNIQ--ref-00000018-QINU`"'
~100% (oral; not significantly affected by food)'"`UNIQ--ref-00000493-QINU`"'
~100% both components
~100% from subcutaneous depot (by definition of the route)
~12% (extensive metabolizers); ~96% (poor metabolizers)
~14% (extensive hepatic first-pass)'"`UNIQ--ref-0000001C-QINU`"'
~14% (oral; substantial first-pass); ~97% (subcutaneous); ~17% (nasal)'"`UNIQ--ref-00000016-QINU`"'
~15% (extensive hepatic first-pass)
~15% (oral; highly variable due to extensive and variable first-pass metabolism)'"`UNIQ--ref-00000022-QINU`"'
~17% (oral; food slightly reduces absorption)'"`UNIQ--ref-000003D6-QINU`"'
~20% (oral; hydrophilic, minimal CYP metabolism, mostly excreted unchanged in bile)'"`UNIQ--ref-000000FD-QINU`"'
~20% (oral; valacyclovir prodrug raises this to ~55%)'"`UNIQ--ref-00000910-QINU`"'
~20-35% (oral; extensive first-pass via CYP3A4 with R/S enantiomer differences)'"`UNIQ--ref-00000A6C-QINU`"'
~22–25%
~25% (extensive hepatic first-pass)
~25% (high first-pass)
~25% (oral)'"`UNIQ--ref-00000019-QINU`"'
~25% (oral, with extensive first-pass)'"`UNIQ--ref-00000023-QINU`"'
~25% (oral; extensive first-pass)'"`UNIQ--ref-0000001B-QINU`"'
~25% (oral; food does not affect absorption)'"`UNIQ--ref-0000005A-QINU`"'
~25% (oral; food reduces absorption ~40%)'"`UNIQ--ref-000004CE-QINU`"'
~25-35% (extensive first-pass), increased by food which slows absorption and reduces orthostatic risk'"`UNIQ--ref-0000001C-QINU`"'
~25-40% (oral; extensive first-pass)'"`UNIQ--ref-00000021-QINU`"'
~25-50% (oral; substantial first-pass via NAT2 acetylation, phenotype-dependent)'"`UNIQ--ref-00000688-QINU`"'
~26% (oral; prodrug hydrolyzed by intestinal esterases to active olmesartan; not affected by food)'"`UNIQ--ref-0000056D-QINU`"'
~28% (oral; food slows but does not reduce absorption)'"`UNIQ--ref-00000C33-QINU`"'
~30% (high first-pass)
~30% (oral)'"`UNIQ--ref-00000021-QINU`"'
~30% (oral)'"`UNIQ--ref-0000117D-QINU`"'
~30-65% (oral; acid-labile, hence enteric-coated formulations; food affects absorption variably)'"`UNIQ--ref-00000D3F-QINU`"'
~33%
~33% (extensive first-pass via CYP2C9 and CYP3A4)'"`UNIQ--ref-000000BD-QINU`"'
~33% (oral; fruit juices including grapefruit, orange, and apple reduce absorption substantially via OATP1A2 inhibition — distinctive interaction not seen with most other H1s)'"`UNIQ--ref-00000CCD-QINU`"'
~33-55% (IR); reduced by food'"`UNIQ--ref-0000001B-QINU`"'
~35% (oral, extensive first-pass; not used orally for systemic effect); ~100% (IV)'"`UNIQ--ref-00000021-QINU`"'
~36% (oral)'"`UNIQ--ref-00000C93-QINU`"'
~37% (oral, as axetil prodrug; food modestly improves absorption)'"`UNIQ--ref-00000FFA-QINU`"'
~37% (oral; food does not affect)'"`UNIQ--ref-00000A23-QINU`"'
~37% (oral; food reduces absorption modestly)'"`UNIQ--ref-000003FD-QINU`"'
~38% (oral; non-acidic prodrug improves GI tolerability over many other NSAIDs)'"`UNIQ--ref-000011FA-QINU`"'
~4% (extensive first-pass metabolism)'"`UNIQ--ref-0000001E-QINU`"'
~40%
~40% (oral); food and formulation substantially alter the absorption profile'"`UNIQ--ref-0000001E-QINU`"'
~40% (oral; extensive first-pass via CYP3A4)'"`UNIQ--ref-00000643-QINU`"'
~40% (oral; food does not significantly affect)'"`UNIQ--ref-00000EB3-QINU`"'
~40-60% (oral, with significant first-pass)'"`UNIQ--ref-00000027-QINU`"'
~44%
~45% (oral)'"`UNIQ--ref-00000C73-QINU`"'
~45% (oral; substantially higher than sumatriptan's ~14%)'"`UNIQ--ref-00000013-QINU`"'
~45%'"`UNIQ--ref-00000027-QINU`"'
~48% intranasal
~5% intranasal
~5-20% (extensive first-pass), highly variable between individuals'"`UNIQ--ref-00000024-QINU`"'
~50%
~50% (highly variable)
~50% (oral); systemic absorption from ophthalmic application is clinically meaningful via nasolacrimal drainage'"`UNIQ--ref-0000001C-QINU`"'
~50% (oral)'"`UNIQ--ref-00000027-QINU`"'
~50% (oral)'"`UNIQ--ref-000002C5-QINU`"'
~50% (oral; highly variable)'"`UNIQ--ref-00000CB4-QINU`"'
~50% (oral; highly variable, 10-100%, hence the standard 1:2 IV-to-PO conversion)'"`UNIQ--ref-00000223-QINU`"'
~50% (oral; not significantly affected by food)'"`UNIQ--ref-000001FC-QINU`"'
~50% (oral; reduced by buffering and enteric coating but onset clinically similar)'"`UNIQ--ref-00000028-QINU`"'
~50% (oral; substantial first-pass)'"`UNIQ--ref-00000024-QINU`"'
~50% (variable, CYP2D6-dependent for analgesic effect).
~50% IR (extensive first-pass via CYP3A4); ER products release-rate-limited'"`UNIQ--ref-0000074E-QINU`"'
~50-60% (oral; food enhances)
~50-60% (oral; substantial first-pass metabolism)'"`UNIQ--ref-0000002A-QINU`"'
~53% (oral)'"`UNIQ--ref-00000024-QINU`"'
~55% (oral)'"`UNIQ--ref-00000016-QINU`"'
~55% bioavailability of acyclovir after valacyclovir oral (vs ~20% from oral acyclovir directly)'"`UNIQ--ref-000005D7-QINU`"'
~58% (extended-release); ~80% (immediate-release)'"`UNIQ--ref-00000021-QINU`"'
~6% IR oral (substantial first-pass to active N-desethyl metabolite, which contributes most of the antimuscarinic adverse effects); transdermal bypasses first-pass and is better tolerated'"`UNIQ--ref-000006E2-QINU`"'
~6-13% inhaled lung deposition; ~10% oral (Entocort EC; extensive first-pass via CYP3A4 — this is the basis of the favorable hepatic-targeted local-effect profile in IBD)'"`UNIQ--ref-000009A6-QINU`"'
~60%
~60% (oral); ~100% (IM)'"`UNIQ--ref-00000027-QINU`"'
~60% (oral)'"`UNIQ--ref-00000379-QINU`"'
~60% (oral)'"`UNIQ--ref-00000D5A-QINU`"'
~60% (oral; food does not affect absorption)'"`UNIQ--ref-00000B85-QINU`"'
~60% (oral; phenoxymethyl modification makes it acid-stable, unlike penicillin G which is destroyed by gastric acid)'"`UNIQ--ref-00000E77-QINU`"'
~60% (oral; substantially increased with high-fat meal)'"`UNIQ--ref-00001093-QINU`"'
~60% from subcutaneous depot (reduced by reversible albumin binding via the myristic acid side chain that also extends duration)'"`UNIQ--ref-00001375-QINU`"'
~60-87% (oral; high and more consistent than codeine or hydrocodone, making efficacy less CYP2D6-genotype-dependent)'"`UNIQ--ref-0000001E-QINU`"'
~60-87% oxycodone (high and predictable, less CYP-genotype-dependent than codeine or hydrocodone); 85-98% acetaminophen'"`UNIQ--ref-000014E3-QINU`"'
~60–70% (oral)
~62%
~63% (oral)'"`UNIQ--ref-00000532-QINU`"'
~63% (oral; extensive first-pass)'"`UNIQ--ref-00000015-QINU`"'
~64% (oral)'"`UNIQ--ref-00000016-QINU`"'
~64% (oral; not significantly affected by food)'"`UNIQ--ref-0000015F-QINU`"'
~64% from SC depot'"`UNIQ--ref-00001104-QINU`"'
~64-90% (oral; increases at higher doses and with multi-day dosing)'"`UNIQ--ref-000008E9-QINU`"'
~65% (oral)'"`UNIQ--ref-0000001E-QINU`"'
~65% (oral)'"`UNIQ--ref-00000784-QINU`"'
~65% (oral)'"`UNIQ--ref-00000AB1-QINU`"'
~65% (oral)'"`UNIQ--ref-000013F6-QINU`"'
~67% (oral)'"`UNIQ--ref-00000B26-QINU`"'
~70% (oral)'"`UNIQ--ref-0000001B-QINU`"'
~70% (oral)'"`UNIQ--ref-00000022-QINU`"'
~70% (oral)'"`UNIQ--ref-000008C5-QINU`"'
~70% (oral; bioavailability and absorption are improved with food)'"`UNIQ--ref-00000355-QINU`"'
~70% (oral; reduced by divalent cations — antacids, iron, calcium, dairy)'"`UNIQ--ref-00000939-QINU`"'
~70-85% (oral)'"`UNIQ--ref-00000027-QINU`"'
~70-90% at typical doses; saturable at high doses (>500 mg)
~72% (with food); much lower fasting (~36%)
~72% from SC depot'"`UNIQ--ref-00001480-QINU`"'
~72% oral; ~85% smoked'"`UNIQ--ref-00000066-QINU`"'
~75%
~75% (IR, rises with multi-dose administration due to saturable first-pass)'"`UNIQ--ref-0000001E-QINU`"'
~75% (oral, as the active carboxylate after hepatic esterase activation)'"`UNIQ--ref-00000E95-QINU`"'
~75% (oral; absorption improved with fat-containing meal)
~75% (oral; fat-soluble, absorption requires intact biliary/lipid digestion)'"`UNIQ--ref-00000331-QINU`"'
~75-85% (oral); ~60% (transdermal at steady state)'"`UNIQ--ref-00000027-QINU`"'
~75–90% (oral)
~77% (oral; not affected by food or antacids)'"`UNIQ--ref-0000011E-QINU`"'
~78% (oral; high-fat meal modestly reduces but is not clinically significant)'"`UNIQ--ref-00000553-QINU`"'
~80% (oral)'"`UNIQ--ref-0000001B-QINU`"'
~80% (oral)'"`UNIQ--ref-0000001E-QINU`"'
~80% (oral)'"`UNIQ--ref-00000029-QINU`"'
~80% (oral)'"`UNIQ--ref-00000310-QINU`"'
~80% (oral)'"`UNIQ--ref-00000BEC-QINU`"'
~80% (oral)'"`UNIQ--ref-00000E2C-QINU`"'
~80% (oral; predictable absorption — a substantive practical advantage over furosemide whose oral absorption is 10-100% variable)'"`UNIQ--ref-00000B47-QINU`"'
~80% (oral; reduced by significant first-pass)'"`UNIQ--ref-00000EFA-QINU`"'
~80-100% (oral)'"`UNIQ--ref-00000027-QINU`"'
~80-100% with food at 15-20 mg doses (10 mg dose: ~80% without food); '''must be taken with food''' at therapeutic doses'"`UNIQ--ref-00000514-QINU`"'
~80-95% (oral; more reliable than furosemide, comparable to torsemide)'"`UNIQ--ref-00000DE4-QINU`"'
~80-99% (oral)'"`UNIQ--ref-00000868-QINU`"'
~82%
~82% SC
~85-90% (oral; not significantly affected by food)'"`UNIQ--ref-00000955-QINU`"'
~85-98% (oral)'"`UNIQ--ref-000006A6-QINU`"'
~87% (oral)'"`UNIQ--ref-00000024-QINU`"'
~87% (oral)'"`UNIQ--ref-00000766-QINU`"'
~89% (oral)'"`UNIQ--ref-00000021-QINU`"'
~90% (low first-pass)
~90% (oral)'"`UNIQ--ref-00000018-QINU`"'
~90% (oral)'"`UNIQ--ref-00000024-QINU`"'
~90% (oral)'"`UNIQ--ref-00000027-QINU`"'
~90% (oral)'"`UNIQ--ref-00000DFF-QINU`"'
~90% (oral)'"`UNIQ--ref-00001140-QINU`"'
~90% (oral)'"`UNIQ--ref-00001443-QINU`"'
~90% (oral, low first-pass)'"`UNIQ--ref-0000001C-QINU`"'
~90% (oral; food increases absorption)'"`UNIQ--ref-000008A4-QINU`"'
~90% (oral; not affected by food but reduced by divalent cations)'"`UNIQ--ref-00000D83-QINU`"'
~93% (oral); ~90% (rectal)'"`UNIQ--ref-00000027-QINU`"'
~93% (oral)'"`UNIQ--ref-00000ED4-QINU`"'
~95% (oral)'"`UNIQ--ref-0000001F-QINU`"'
~95% (oral)'"`UNIQ--ref-0000002A-QINU`"'
~95% (oral)'"`UNIQ--ref-0000149E-QINU`"'
~95% (oral)'"`UNIQ--ref-000014C4-QINU`"'
~95% (oral; reduced by dairy, antacids, iron via divalent-cation chelation, though less than for tetracycline itself)'"`UNIQ--ref-0000047E-QINU`"'
~96% (oral)'"`UNIQ--ref-00000AD2-QINU`"'
~96% after red blood cell hydrolytic cleavage releases dextroamphetamine'"`UNIQ--ref-00000018-QINU`"'
~98% (oral)'"`UNIQ--ref-00000026-QINU`"'
~99% (caffeine)
~99% (oral)'"`UNIQ--ref-0000002A-QINU`"'
~99% (oral; matched 1:1 IV-to-PO conversion)'"`UNIQ--ref-00000CF6-QINU`"'
≥90% (linear pharmacokinetics, distinguishing it favorably from gabapentin's saturable LAT-1 absorption)'"`UNIQ--ref-00000027-QINU`"'
Search
pregnancy:
Avoid; neonatal opioid withdrawal documented.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
legal:
[[USLegal:Schedule IV|Schedule IV controlled substance]] in US (tramadol was reclassified from non-controlled to Schedule IV in 2014 after recognition of dependence risk) (1)
Error in "where" parameter: the string "--" cannot be used within #cargo_query.
There are no results for this report.
Search
Search
Drilldown: Medicines
Add topic
& bioavailability:
Tramadol ~75% (oral); acetaminophen 85-98%'"`UNIQ--ref-00001531-QINU`"' 
generic:
duration: (Click arrow to add another value)